Resources from the same session
2886 - Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: data from KEYNOTE-407
Presenter: Julien Mazieres
Session: Poster Discussion session - NSCLC, metastatic 2
Resources:
Abstract
4406 - Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed 2 years of pembrolizumab (pembro)
Presenter: Roy S. Herbst
Session: Poster Discussion session - NSCLC, metastatic 2
Resources:
Abstract
4342 - Pembrolizumab in performance status 2 patients with non-small-cell lung cancer (NSCLC): results of the PePS2 trial
Presenter: Gary Middleton
Session: Poster Discussion session - NSCLC, metastatic 2
Resources:
Abstract
1767 - A randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC – the ETOP and EORTC SPLENDOUR trial.
Presenter: Solange Peters
Session: Poster Discussion session - NSCLC, metastatic 2
Resources:
Abstract
2936 - nab-Paclitaxel + Carboplatin Induction Followed by nab-Paclitaxel Maintenance in Squamous Non-Small Cell Lung Cancer (NSCLC): Results From the ABOUND.sqm Study
Presenter: David Spigel
Session: Poster Discussion session - NSCLC, metastatic 2
Resources:
Abstract
Slides
4580 - IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomised Phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel in 1L advanced squamous NSCLC
Presenter: Mark Socinski
Session: Poster Discussion session - NSCLC, metastatic 2
Resources:
Abstract
2984 - IMpower150: clinical safety, tolerability and immune-related adverse events in a Phase III study of atezolizumab (atezo) + chemotherapy (chemo) _ bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC
Presenter: Martin Reck
Session: Poster Discussion session - NSCLC, metastatic 2
Resources:
Abstract
Poster Discussion session - NSCLC, metastatic 2 - Invited Discussant LBA62, LBA63 and 1384PD
Presenter: Simon Ekman
Session: Poster Discussion session - NSCLC, metastatic 2
Resources:
Slides
Webcast